AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
dydrogesterone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroids, progestogens | 975 | 152-62-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit OVULATION.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 28 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,STK33,TEK,TGFBR1 | 27 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | SOLVAY | |
| Dec. 1, 1965 | PMDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Abortion spontaneous | 427.10 | 55.23 | 102 | 910 | 53954 | 90573481 |
| Maternal exposure during pregnancy | 352.29 | 55.23 | 135 | 877 | 359928 | 90267507 |
| Ovarian hyperstimulation syndrome | 230.44 | 55.23 | 42 | 970 | 5820 | 90621615 |
| Placenta accreta | 72.26 | 55.23 | 10 | 1002 | 231 | 90627204 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 234.37 | 50.09 | 39 | 708 | 5321 | 110583231 |
| Maternal exposure during pregnancy | 101.54 | 50.09 | 44 | 703 | 254839 | 110333713 |
| Placenta accreta | 77.90 | 50.09 | 10 | 737 | 217 | 110588335 |
| Exposure during pregnancy | 70.04 | 50.09 | 30 | 717 | 167394 | 110421158 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G03DB01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS Pregnadien derivatives |
| ATC | G03FA14 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, fixed combinations |
| ATC | G03FB08 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, sequential preparations |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D011372 | Progestins |
| CHEBI has role | CHEBI:59826 | progestin |
Related Drugs by ATC class:
G03DB Pregnadien derivatives 7 drugs
G03FA Progestogens and estrogens, fixed combinations 15 drugs
G03FB Progestogens and estrogens, sequential preparations 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Luteal phase support | indication | 6738008 | |
| Prevention of premature ovulation during controlled ovarian stimulation | indication | 732970000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Progesterone receptor | Nuclear hormone receptor | AGONIST | Ki | 6.90 | IUPHAR | CHEMBL | |||
| Nuclear receptor subfamily 2 group E member 1 | Nuclear hormone receptor | Kd | 4.56 | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| N0000167428 | NUI |
| D01217 | KEGG_DRUG |
| C0013340 | UMLSCUI |
| CHEBI:31527 | CHEBI |
| CHEMBL1200853 | ChEMBL_ID |
| DB00378 | DRUGBANK_ID |
| D004394 | MESH_DESCRIPTOR_UI |
| 9051 | PUBCHEM_CID |
| 2878 | IUPHAR_LIGAND_ID |
| 970 | INN_ID |
| 90I02KLE8K | UNII |
| 3706 | RXNORM |
| 001296 | NDDF |
| 126093005 | SNOMEDCT_US |
| 43753001 | SNOMEDCT_US |
| 90I02KLE8K | INXIGHT DRUGS |
Pharmaceutical products:
None